No­var­tis flex­es PhI­II win for oral BTK in­hibitor in chron­ic spon­ta­neous ur­ticaria

Last year
R&D

De­nali, Take­da scrap PhI Alzheimer's drug due to safe­ty sig­nals, 'rapid­ly evolv­ing' land­scape

Last year
R&D

Mi­rati an­nounces CEO res­ig­na­tion, then a $300M pub­lic of­fer­ing af­ter dis­clos­ing clin­i­cal plans

Last year
People
Financing

No­vavax plans to have up­dat­ed Covid vac­cine to mar­ket by Sep­tem­ber — but will it be ready in time?

Last year
Pharma
Coronavirus

Evo­lus puts on 'y­outh­ful' new look for frown line treat­ment Jeu­veau

Last year
Pharma
Marketing

Zyn­te­glo and Skysona com­bine for 16 pa­tient starts since ap­provals last year

Last year
Pharma

Mar­ket­ingRx roundup: An­a­lyst group finds no ‘ob­vi­ous’ link to GLP-1s and sui­ci­dal ideation; Am­gen de­buts new ...

Last year
Pharma
Marketing

Bris­tol My­ers in­tro­duces re­al pa­tients in dig­i­tal and so­cial So­tyk­tu pso­ri­a­sis cam­paign

Last year
Pharma
Marketing

FDA's up­dat­ed rules for drug ad­ver­tis­ing for TV and ra­dio near the fin­ish line

Last year
Pharma
Marketing

DOD taps Val­isure to car­ry out drug qual­i­ty re­views amid gener­ic short­ages, con­cerns

Last year
FDA+
Manufacturing

Oculis eye drop se­cures an­oth­er late-stage win, this time in post-cataract surgery in­flam­ma­tion and pain 

Last year
R&D

Emer­gent com­mits to lay­offs and C-suite trim­mings, no longer fo­cus­ing on CD­MO ac­tiv­i­ty

Last year
People
Manufacturing

Beam takes its time to the clin­ic; As­pen gets clear­ance to test Parkin­son's cell ther­a­py in hu­mans

Last year
News Briefing

Up­dat­ed: Lil­ly's rev­enues rise 28% in Q2 thanks to surge in de­mand for di­a­betes drug Moun­jaro

Last year
Pharma

Up­dat­ed: Bay­er cuts PhII or­phan drug as it ups R&D spend­ing, ques­tions swirl around new CEO’s next moves

Last year
R&D

Mer­ck en­lists As­tex to search for p53 can­cer drug in ex­pand­ed deal

Last year
Deals

Up­dat­ed: No­vo Nordisk's semaglu­tide in­jec­tion re­duces car­dio­vas­cu­lar events by 20% in vast SE­LECT tri­al

Last year
R&D

Nek­tar sues Lil­ly, claim­ing its in­ter­est in biotech’s au­toim­mune drug ‘waned dra­mat­i­cal­ly’ af­ter buy­ing Der­mi­ra

Last year
Pharma
Law

Nas­daq threat­ens to delist Taysha Gene Ther­a­pies

Last year
Financing

J&J inks an­oth­er Ste­lara biosim­i­lar set­tle­ment, push­ing Formy­con’s can­di­date in­to po­ten­tial 2025 launch

Last year
Pharma

Re­al Chem­istry taps two vet­er­ans to lead its cri­sis com­mu­ni­ca­tions and so­cial im­pact busi­ness­es

Last year
People
Marketing

Hos­pi­tal groups ask Con­gress to re­form 340B pro­gram, crack down on con­tract phar­ma­cy re­stric­tions

Last year
Pharma
FDA+

Pfiz­er, Gates Foun­da­tion and oth­ers plan to boost pro­duc­tion of con­tra­cep­tive Sayana Press

Last year
Manufacturing

Vista­gen's pos­i­tive PhI­II for so­cial anx­i­ety nasal spray push­es stock price up 1,000+%

Last year
Pharma
First page Previous page 299300301302303304305 Next page Last page
A service from the Financial Times